Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Volume 1870, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbadis.2023.166880
Keywords
Colorectal cancer; Consensus molecular subtypes; Signaling pathways; Small -molecule drug; Drug combination
Ask authors/readers for more resources
This review focuses on the current status and strategies of small molecule drugs for colorectal cancer (CRC) therapy. Despite the challenges posed by CRC's genetic susceptibility and molecular heterogeneity, new approaches such as dual/multiple-target drugs, drug repurposing, and combination therapies provide insights for improving CRC treatment in the future.
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the world's fourth most deadly cancer. CRC, as a genetic susceptible disease, faces significant challenges in optimizing prognosis through optimal drug treatment modalities. In recent decades, the development of innovative small-molecule drugs is expected to provide targeted interventions that accurately address the different molecular characteristics of CRC. Although the clinical application of single-target drugs is limited by the heterogeneity and high metastasis of CRC, novel small-molecule drug treatment strategies such as dual/multiple-target drugs, drug repurposing, and combination therapies can help overcome these challenges and provide new insights for improving CRC treatment. In this review, we focus on the current status of a range of small molecule drugs that are being considered for CRC therapy, including single-target drugs, dual/multiple-target drugs, drug repurposing and combination strategies, which will pave the way for targeting CRC vulnerabilities with small-molecule drugs in future personalized treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available